46 results about "Substantia nigra" patented technology

The invention discloses a method for establishing a clinical interpretable PD diagnosis model based on multi-sequence magnetic resonance brain characteristics, and aims to promote more accurate diagnosis of PD by extracting multi-level and multi-dimensional brain image information from multi-modal brain magnetic resonance image data and constructing a diagnosis model by means of machine learning. The method comprises the steps of brain image data preprocessing, feature standardization and screening, model construction, independent verification set and cross-disease set verification, a group of brain function and metabolism features taking a PD abnormal perfusion mode and nigra iron distribution as the principal thing are obtained, and the constructed model has high diagnosis efficiency in a training set and the independent verification set. Secondly, clinical interpretability of the model is promoted through curve calibration, DCA and CIC analysis and correlation analysis of predicted individual scores obtained based on the model and clinical symptoms. The diagnostic efficiency of the constructed PD diagnostic model in different disease sets shows that the model has good diagnostic efficiency on PSP and MSA diseases.

The invention relates to an application of a traditional Chinese medicine composition in preparation of a medicine for Parkinson's disease, which is characterized in that the traditional Chinese medicine composition is prepared from ginseng, rehmannia, cistanche, salvia miltiorrhiza, polygala tenuifolia, rhizoma acori graminei and curcuma aromatica. The composition provided by the invention can obviously improve mouse dyskinesia caused by a Parkinson's disease model, reduce level rise of IL-1beta, IL-18 and TNF-alpha caused by the mouse Parkinson's disease model, obviously increase the level of DA in nigra of brain tissues of rats with Parkinson's disease, and reduce the levels of IL-1beta and IL-6, and has a good treatment effect on Parkinson's disease.

The invention relates to a probiotic preparation for improving Parkinson's disease and an application of the probiotic preparation. The bacterial strains in the probiotic preparation comprise an Ackermania muciniphila Akk11 bacterial strain and a Bifidobacterium breve BBr60 bacterial strain. The invention further relates to a preparation method of the probiotic preparation for improving the Parkinson's disease and an application of the probiotic preparation for improving the Parkinson's disease, wherein the bacterial strains in the probiotic preparation comprise the Ackermania muciniphila Akk11 bacterial strain and the Bifidobacterium breve BBr60 bacterial strain. The invention develops a brand-new probiotic compounding mode and a brand-new probiotic intervention strategy for improving the Parkinson's disease, that is, the Akk11 strain and the BBr60 strain are compounded, and the two strains are found to have potential interaction and can be matched with each other, so that a synergistic effect is achieved on the aspect of improving the Parkinson's disease, and the effect of improving the Parkinson's disease is achieved. Specifically, the traditional Chinese medicine composition synergistically improves dyskinesia caused by Parkinson's disease, reduces expression of related inflammatory factors in nigra, promotes generation of anti-inflammatory factors to relieve neurological inflammation, inhibits activation of inflammasome NLPR3 in nigra, and further inhibits brain inflammation.

The present invention discloses a method for automatically segmenting deep gray matter structures (caudate nucleus, putamen, globus pallidus, substantia nigra, red nucleus, dentate nucleus) of the brain based on T1W and QSM by combining deep learning with personalized atlas, including the steps of: collecting T1W and QSM magnetic resonance data, and manually annotating deep gray matter structures of the brain by doctors; extracting feature vectors of T1W brain images; performing unsupervised clustering on the feature vectors of all T1W brain images, selecting representative images and doctor's annotations to form a personalized atlas; registering the T1W images and annotations in the personalized atlas with other subjects' T1W images to obtain preliminary segmentation results, forming training set data; constructing a deep learning network model based on the attention mechanism; and training the model to segment deep gray matter structures of the brain. The present invention uses the contrast advantages of T1W and QSM images to accurately and automatically segment deep gray matter structures of the brain, and is expected to be used in brain imaging research and auxiliary clinical diagnosis of movement disorders such as Parkinson's disease in the future.

The invention provides an application of N-acyl dopamine family lipids in prevention and treatment of drug-induced motor complications of Parkinson's disease, and belongs to the field of biological medicine. The invention provides the application of the NADs compound as the levodopa partner medicine for preventing or treating levodopa-induced dyskinesia for the first time. According to the invention, an LID animal model is subjected to 6-hydroxydopamine midbrain nigra positioning injection and levodopa intraperitoneal injection molding as research objects, and the effect of NADs in improving LID is researched. The result shows that the NADs can significantly improve the drug-induced PD motor complication LID, indicating that the NADs compound can be used as a partner drug to assist levodopa in treating PD.

Described herein are techniques for identifying regions of substantia nigra reticulata (SNR) and regions of substantia nigra compact dorsal (SNCD) in histology images and quantifying a number of dopaminergic neural cells within the images. In some embodiments, an image of a section of a brain may be input into a first machine learning model to obtain a first segmentation map comprising pixel-wise labels indicative of whether a corresponding pixel in the image depicts a region of SNR or SNCD. In some embodiments, the image (and, optionally, the first segmentation map) may also be input to a second machine learning model trained to generate a second segmentation map comprising pixel-wise labels indicating whether a corresponding pixel of the image depicts a dopaminergic neural cell or neural background tissue. The number of cells within the image may be determined based on the second segmentation map.

The invention discloses a system for intelligently and automatically identifying and analyzing brain nigra high echo based on a transcranial ultrasonic image to assist in diagnosing Parkinson's disease, and relates to the technical field of image identification. Comprising an ultrasonic image data collection and preprocessing module, a deep learning model construction and training module, a nigra region accurate identification and segmentation module, a nigra region area measurement and statistical analysis module and a diagnosis result verification and visual output module. According to the method, an intelligent automatic identification model based on deep learning is constructed, and model optimization is carried out by using a large amount of manually labeled Parkinson's disease and health contrast ultrasonic image data, so that efficient identification segmentation and area measurement of a nigra region in a transcranial ultrasonic image are realized; and meanwhile, the performance of the model is comprehensively evaluated by using indexes of sensitivity, specificity and accuracy, so that the accuracy of an output result is ensured.

The invention belongs to the technical field of medicines, and discloses application of poliumoside to prevention and treatment of Parkinson's disease. Specifically, the invention discloses application of poliumoside as a compound shown in a formula (I) in the aspect of preventing and treating Parkinson's disease. Pharmacological experiments prove that after 14 days of administration of the poliumoside, the impairment of motor coordination function caused by MPTP-induced Parkinson's disease can be obviously improved, the reduction of the expression level of brain nigra tyrosine hydroxylase caused by MPTP is improved, and the result shows that the poliumoside has obvious pharmacological activity for preventing and treating Parkinson's disease. Therefore, poliumoside can be used for preparing the medicine for preventing and treating Parkinson's disease, and has high clinical application value and development prospect.

The invention discloses a tree shrew Parkinson's disease model making method which comprises the following specific steps: (1) Macrozam preparation: weighing required Macrozam under a sterile condition, and dissolving the Macrozam in sterilized ultrapure water to prepare a Macrozam working solution with the concentration of 10 mg / mL; (2) gavage: gavage is conducted on the tree shrew with Macrozamine using liquid, the dosage is 40-80 mg / kg according to the mass of the tree shrew body, and a stable tree shrew Parkinson's disease model is established after normal feeding is conducted for two weeks. According to the method, the tree shrew is subjected to intragastric administration with Macrozamine, the dosage is 40-80 mg / kg, and a stable tree shrew Parkinson's disease model can be established after two weeks. According to the scheme, three transformation medical bottlenecks of a traditional model are overcome for the first time through tree shrew nigra-striatum pathway anatomy conservative property, oral transformation advantage and dosage precise control three-dimensional innovation: (1) whole course simulation; (2) channel-level fidelity; and (3) high-value prediction. The model provides an irreplaceable standardized platform for Parkinson's disease mechanism research and clinical transformation.

The application discloses a device and method for detecting mouse motion learning behavior, and belongs to the field of animal behavior detection. The device comprises a mouse motion runway, a dark box at the terminal of the runway, and a camera for recording the motion process of the mouse. The runway is provided with a plurality of replaceable metal rods in the transverse direction. The metal rods are composed of any one or both of white metal rods and black metal rods. The runway composed of the black metal rods and the white metal rods is provided with any one of the metal rods for electrification, and the electrified metal rods are discontinuously arranged. The mouse is shocked by stepping on the electrified metal rods. The method of the application replaces the metal rods to form different runways, trains the mouse to reach the dark box through the different runways, and obtains the motion learning behavior ability of the mouse at different stages. The process of motion learning is simulated through programmed training. The role of the brain regions in the process of motion learning behavior is determined by regulating the regions of the substantia nigra or the striatum corresponding to the motion learning.

The application provides application of N-acyl dopamine family lipids in prevention and treatment of drug-induced Parkinson's disease motor complications, and belongs to the field of biological medicine. The application first proposes that the NADs compound can be used as a levodopa companion drug for preventing or treating levodopa-induced dyskinesia. The application takes 6-hydroxydopamine intracerebral injection and intraperitoneal injection of levodopa of an LID animal model as a research object, and studies the effect of NADs on improving LID. The results show that the NADs of the application can significantly improve the drug-induced PD motor complications LID, and it is proved that the NADs compound can be used as a companion drug to assist levodopa in treating PD.

The invention relates to an application of a substance for detecting high signals of dorsal-lateral nigra in preparation of a product for detecting alpha-synucleinopathies. The Parkinson's disease and rapid eye movement sleep behavior disorder diagnosis system is constructed based on an analysis strategy of magnetic sensitive weighted imaging, the diagnosis system can be effectively applied to auxiliary diagnosis, the diagnosis sensitivity of the Parkinson's disease is 93.8%, the specificity is 96.7%, the diagnosis sensitivity of the rapid eye movement sleep behavior disorder is 66.7%, and the diagnosis sensitivity of the rapid eye movement sleep behavior disorder is 96.7%. The kit has the advantages that the sensitivity is high, the specificity is 98.0%, the rapid eye movement sleep behavior disorder or the Parkinson's disease can be subjected to etiological typing, systematic management and effective prevention of patients are facilitated, the clinical diagnosis uncertainty of the Parkinson's disease is remarkably reduced through the diagnosis mode, early screening diagnosis is promoted, and the clinical diagnosis and treatment level is improved.

The invention provides a traditional Chinese medicine composition for treating Parkinson's depression and a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicines. The traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 1-10 parts of radix acanthopanacis semticosi and 1-10 parts of bulbus lilii. The invention also provides a preparation method of the traditional Chinese medicine composition, which comprises the following steps: taking the acanthopanax and the lily, adding water to soak, heating, refluxing and extracting, and combining filtrate to obtain the traditional Chinese medicine composition. Animal experiments find that the acanthopanax-lily traditional Chinese medicine composition has a good treatment effect on Parkinson depression for the first time, and can remarkably improve dyskinesia and depression symptoms, regulate neurotransmitter disorder, relieve damage to nigra and hippocampal neurons and reduce the level of inflammatory factors in serum. After being taken for a long time, the traditional Chinese medicine composition disclosed by the invention can improve depression and life quality, slow down the progress of Parkinson disease and reduce the use of Parkinson drugs.

The present invention relates to cannabidiol derivatives, their preparation methods and uses, particularly in the treatment of nervous system disorders (e.g. The present invention discloses the use of the above cannabidiol in the prevention and treatment of chronic kidney disease (such as Parkinson's disease). The derivatives were screened from a series of synthetic derivatives, and the results of animal experiments showed that The above cannabidiol derivatives improved the balance beam scores of Parkinson's disease model animals. It reduces dopamine levels and tyrosine hydroxylase (T hydroxylase) levels in the substantia nigra (SubN) of the brain. H) It can improve the positive rate of cells and treat various diseases such as epilepsy and Parkinson's disease. It is useful in the research and development of therapeutic drugs for diseases, and has high application value.

Disclosed in the present invention are a cannabidiol derivative, a preparation method therefor and an application thereof, particularly an application in preventing and treating nervous system diseases (such as Parkinson's disease). The cannabidiol derivative is obtained by screening from a series of synthetic derivatives. An animal testing result shows that the cannabidiol derivative can reduce the balance beam score of a Parkinson's model animal and improve the dopamine level and the tyrosine hydroxylase (TH) cell positive rate in substantia nigra (SubN), can be used for drug development and research of various diseases such as epilepsy and Parkinson's disease, and has better application value.

The present invention discloses a cannabidiol derivative, its preparation method and application, especially the application in the prevention and treatment of nervous system diseases (such as epilepsy, Parkinson's disease). The above-mentioned cannabidiol derivative is screened from a series of synthetic derivatives. The results of animal experiments show that these compounds can effectively shorten the duration of epileptic seizures in experimental animals, improve the symptoms of epileptic seizures in experimental animals, reduce the balance beam score of Parkinson's model animals, increase the dopamine level and the positive rate of tyrosine hydroxylase (TH) cells in the substantia nigra (SubN) of the brain, and can be used for the drug development and research of various diseases such as epilepsy and Parkinson's disease, and has better application value.

To provide a method for diagnosing progressive supranuclear palsy.SOLUTION: A method for assisting in diagnosis of progressive supranuclear palsy comprises: calculating a midbrain uptake ratio (MUR) obtained by the formula (I): MUR=(positron emission intensity of at least one or more of a midpoint 1 region and a midpoint 2 region of a subject) / (positron emission intensity of at least one or more of a midbrain midpoint 1 region, a substantia nigra midpoint 1 region, and a substantia nigra midpoint 2 region of the subject) using positron emission tomography (PET) and magnetic resonance imaging (MRI) using an MAO-B ligand probe; and comparing the midbrain uptake ratio (MUR) with a reference value for healthy persons, to determine that the subject has progressive supranuclear palsy when the MUR is higher than the reference value.SELECTED DRAWING: Figure 9

The application provides application of a hydroxy pentylbenzoic acid double ester compound L-NRB in treatment of Parkinson's disease. Animal model test proves that L-NRB can effectively improve the MPTP-induced Parkinson's disease mouse behavior index, increase the content of DA and its metabolites DOPAC and HVA in the brain, inhibit the loss of dopamine neurons in the substantia nigra and striatum, inhibit the expression of inflammatory factors and the activation of astrocytes and microglia in the substantia nigra; meanwhile, L-NRB can also inhibit the activity of MAO-B in the striatum. L-NRB has no toxic side effects in vivo and in vitro; has the advantages of high safety, small dosage, long-term stability and the like, and is suitable for further development for actual clinical treatment.

The invention belongs to the technical field of medicines, and particularly relates to application of a Chinese knotweed rhizome and aloe bowel-relaxing capsule to preparation of a medicine for treating Parkinson's disease. The Chinese knotweed rhizome and aloe bowel-relaxing capsule can obviously improve the damage of nigra and striatum dopaminergic neurons of mice suffering from the Parkinson's disease complicated with depression caused by MPTP and CUMS, and inhibit the activation of microglia and astroglia cells; the traditional Chinese medicine composition not only can relieve motion symptoms of mice with Parkinson's disease, but also can remarkably improve non-motion symptoms including mental disorder of the mice with Parkinson's disease, and has a remarkable treatment effect on depression of Parkinson's disease.

The present application relates to a kind of probiotic preparation for improving Parkinson's disease and its application, the strain in the probiotic preparation includes mucinophilic Akkermansia Akkermansia muciniphila Akk11 strain and Bifidobacterium breve Bifidobacterium breve BBr60 strain.The present application develops a brand-new probiotic compound mode and a brand-new probiotic intervention strategy for improving Parkinson's disease, i.e., Akk11 strain and BBr60 strain are compounded, it is found that there is potential interaction between the two, can cooperate with each other, synergistic effect in improving the efficacy of Parkinson's disease, specifically in: synergistically improving the motor disorders caused by Parkinson's disease, reducing the expression of related inflammatory factors in substantia nigra, promoting the generation of anti-inflammatory factors to relieve neurogenic inflammation, inhibiting the activation of inflammasome NLPR3 in substantia nigra to further inhibit brain inflammation.

The application relates to a magnetic resonance imaging image processing method, device, storage medium and electronic equipment, which comprises the following steps: performing spatial alignment and size normalization processing on an original three-dimensional MRI image to obtain a normalized MRI image; performing segmentation on the normalized MRI image to obtain a mask image set containing multiple regions of interest, wherein the regions of interest include a substantia nigra, a striatum and a globus pallidus; performing double-flow factorization coding on brain tissue data corresponding to the mask image set to obtain content features related to pathology and style features related to an imaging domain; performing reconstruction based on the content features and the style features to obtain a reconstructed image; performing double-flow factorization coding based on the reconstructed image, performing physical disturbance and adversarial alignment on the obtained double-flow coding, and obtaining disturbance features; and obtaining the classification corresponding to the original three-dimensional MRI image based on the disturbance features and a classification model obtained through pre-training. The classification accuracy can be improved.

The present invention provides the use of sclareol in the preparation of drugs for inhibiting microglia-mediated inflammation, and belongs to the field of biomedicine technology. The present invention observes inflammatory response indicators through animal intraperitoneal injection of LPS model, BV2 cell LPS stimulation model and substantia nigra α-Syn overexpression PD model mice, and finds that sclareol can inhibit the inflammatory response caused by central microglia, improve the pathological manifestations of Parkinson's disease, and provide a new approach for the treatment of degenerative diseases of the central nervous system.

The invention discloses a function detection system and a function detection method for ocular nigra dopaminergic neurodegeneration. The optical vision equipment stimulates the eyes of the tested object before and after the specific condition that the dopamine level in the tested object is improved, and meanwhile, a stimulation index is recorded; the fundus blood flow detection equipment is used for detecting and recording fundus blood vessel and blood flow parameter change information of the tested object before and after in-vivo dopamine level improvement and before and after visual stimulation so as to generate a blood flow index; the signal processing equipment receives and processes the blood flow index and the stimulation index to obtain a retina nerve blood vessel coupling function index; the computer or the chip receives the retina nerve-blood vessel coupling function index to judge the risk or the result of the brain nigra dopaminergic neurodegeneration. According to the invention, the eyes are used as a detection window, so that the brain nigra dopaminergic neurodegeneration can be rapidly and non-invasively detected, and the method has high sensitivity and specificity.

A method for establishing a cynomolgus monkey animal model of Parkinson's disease belongs to animal experimental technology. Using cynomolgus monkeys as model animals, AAV-SNCA is first injected into the substantia nigra by stereotaxic method, with a total injection volume of 42-48 μl; after an interval of 85-95 days, PAR is injected into the same position again, with a total injection volume of 23-27 μl. The method for establishing an animal model of the present invention is safe and reliable, simulates the pathological, imaging and behavioral results of PD, and has good application prospects.

The present invention discloses a method for establishing a clinically interpretable PD diagnostic model based on multi-sequence magnetic resonance brain features, which aims to promote a more accurate diagnosis of PD by extracting multi-level and multi-dimensional brain imaging information from multimodal brain magnetic resonance imaging data and constructing a diagnostic model with the help of machine learning. The method includes: brain imaging data preprocessing, feature standardization and screening, model construction, independent validation set and cross-disease set validation, and obtains a set of brain function and metabolic characteristics mainly based on PD abnormal perfusion patterns and substantia nigra iron distribution. The constructed model has high diagnostic efficacy in both the training set and the independent validation set. Secondly, the clinical interpretability of the model is promoted by calibration curve, DCA, CIC analysis, and correlation analysis between the predicted individual scores and clinical symptoms obtained based on the model. The diagnostic efficacy of the PD diagnostic model constructed by the present invention in different disease sets shows that the model has good diagnostic efficacy for PSP and MSA diseases.

The invention relates to a fluorescent probe for targeting lipid droplets with long-term retention capacity, a preparation method and application thereof, and belongs to the technical field of fluorescent probes. The structural formula of the fluorescent probe is shown in the specification. The ClogP value of the fluorescent probe is greater than 8, high-specificity targeting to lipid droplets can be realized, and the fluorescent probe can be stably retained in living cells for 72 hours. The fluorescent probe not only can trace abnormal accumulation of lipid droplets in a Parkinson's disease model on a cellular level, but also can realize visual detection of lipid droplet pathological accumulation in a nigra area of a living animal model through intracerebral in-situ injection. The fluorescent probe is obtained by carrying out a Knoevenagel reaction on 4, 4 '-diformyl triphenylamine and benzothiazole-2-acetonitrile, and has the characteristics of simplicity and convenience in synthesis, good biocompatibility, high signal-to-noise ratio and long cell retention time.

This invention relates to the field of pharmaceutical technology for treating motor dysfunction in Parkinson's disease, and particularly to a traditional Chinese medicine preparation for treating motor dysfunction in Parkinson's disease. The formula consists of Cimicifuga rhizome, processed turtle shell, Angelica sinensis, raw licorice root, ginger-processed Pinellia ternata, Gastrodia elata, and scorpion. This invention uses a traditional Chinese medicine formula to treat motor dysfunction in Parkinson's disease. The medicinal materials comply with national regulations for the management of traditional Chinese medicine materials and have undergone clinical testing. The formula is rationally formulated with high synergistic effects and long-lasting and stable efficacy. Based on the principles of traditional Chinese medicine syndrome differentiation and treatment, this formula addresses the deficiency of both liver and kidney, and the insufficiency of qi and blood, with tremor and paralysis attributed to internal liver wind. It significantly improves motor dysfunction and tremor symptoms in Parkinson's disease. This preparation is highly effective, safe, reliable, and has few side effects. It can also significantly reduce the expression levels of tyrosine hydroxylase in the substantia nigra and striatum. This preparation represents a new approach to treating motor dysfunction in Parkinson's disease and has broad prospects in the field of treating this condition.

The invention relates to an application of LncRNA NEAT1 as a diagnostic substance of Parkinson's disease. Specifically, the LncRNA NEAT1 is used as a marker for diagnosing the Parkinson's disease so as to further diagnose whether the structure and the function of a midbrain nigra region are normal or not and whether the midbrain nigra region suffers from the Parkinson's disease or not, and the LncRNA NEAT1 can be used for developing a diagnostic agent or a kit related to the Parkinson's disease. The invention finds that the LncRNA NEAT1 can be used as a marker for diagnosing the Parkinson's disease for the first time.

The present application relates to a kind of Parkinson's disease animal model construction method, which is directly injected into the brain of animal by MPTP in the substantia nigra, and then the characteristic index score of animal is judged according to the characteristic index score standard, one Parkinson's disease animal model only needs to be injected once by MPTP for one animal, which is simple in operation process and short in time, greatly reduces the difficulty of modeling and animal care, which can achieve the purpose of modeling with a small amount of MPTP, thereby improving the modeling efficiency, and since the neurotoxicity response induced by MPTP is irreversible, MPTP is directly injected into the brain to act, which can also avoid the hindrance when MPTP is transmitted to the substantia nigra from other tissues of animal, thereby improving the success rate and stability of modeling.

The invention relates to the technical field of disease model construction, in particular to a construction method of a vascular Parkinson's syndrome composite animal model. The method comprises the following steps: sequentially performing chronic whole-brain hypoperfusion treatment and systemic mitochondrial complex I inhibition treatment on an advanced mammal, and applying the vascular Parkinson's syndrome animal model to preparation of a medicine for screening or evaluating prevention and / or treatment of the vascular Parkinson's syndrome. According to the construction method of the vascular Parkinson's syndrome composite animal model provided by the invention, a stable cerebrovascular lesion and a definite nigra-strike dopamine energy system are simultaneously induced on the same animal individual through an innovative double-strike modeling method; therefore, a brand-new animal model which is highly similar to human diseases in pathology is created.